See more : Freshworks Inc. (FRSH) Income Statement Analysis – Financial Results
Complete financial analysis of Dyadic International, Inc. (DYAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dyadic International, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Home Bancorp Wisconsin, Inc. (HWIS) Income Statement Analysis – Financial Results
- Optima bank S.A. (OPTIMA.AT) Income Statement Analysis – Financial Results
- Daeho Al Co.,Ltd. (069460.KS) Income Statement Analysis – Financial Results
- Shanghai Highly (Group) Co., Ltd. (600619.SS) Income Statement Analysis – Financial Results
- Masaru Corporation (1795.T) Income Statement Analysis – Financial Results
Dyadic International, Inc. (DYAI)
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 2005 | 2004 | 2003 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.90M | 2.93M | 2.40M | 1.60M | 1.68M | 1.30M | 758.42K | 592.89K | 315.71K | 12.52M | 17.13M | 15.60M | 15.38M | 15.88M | 16.74M | 211.27K |
Cost of Revenue | 1.98M | 2.12M | 1.94M | 1.42M | 1.46M | 1.03M | 680.20K | 516.16K | 124.01K | 8.18M | 9.72M | 7.62M | 11.35M | 12.86M | 12.83M | 175.44K |
Gross Profit | 922.96K | 807.11K | 459.39K | 176.99K | 221.38K | 268.17K | 78.22K | 76.72K | 191.70K | 4.35M | 7.41M | 7.99M | 4.04M | 3.03M | 3.91M | 35.83K |
Gross Profit Ratio | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.70% | 10.31% | 12.94% | 60.72% | 34.71% | 43.25% | 51.18% | 26.25% | 19.05% | 23.34% | 16.96% |
Research & Development | 3.30M | 4.50M | 8.39M | 3.87M | 3.96M | 3.32M | 2.20M | 885.60K | 124.01K | 2.19M | 1.00M | 921.71K | 4.24M | 4.90M | 3.62M | 0.00 |
General & Administrative | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 6.11M | 4.99M | 4.48M | 7.15B | 5.32M | 3.76M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 944.12K | 700.78K | 3.42B | 2.81M | 1.86M | 0.00 |
SG&A | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 7.36M | 5.94M | 5.50M | 10.57M | 8.13M | 5.61M | 42.54K |
Other Expenses | 38.42K | 250.00K | 6.09M | 187.39K | 2.30M | 2.04M | 220.72K | 436.92K | 0.00 | 0.00 | 0.00 | 0.00 | -28.70K | -16.79K | 0.00 | 184.07K |
Operating Expenses | 9.15M | 10.92M | 15.09M | 10.14M | 9.48M | 7.84M | 7.45M | 5.88M | 3.84M | 9.55M | 6.94M | 5.87M | 14.77M | 13.01M | 9.24M | 226.61K |
Cost & Expenses | 11.13M | 13.05M | 17.03M | 11.57M | 10.94M | 8.87M | 8.13M | 6.40M | 3.96M | 17.72M | 16.66M | 13.49M | 26.12M | 25.87M | 22.07M | 402.05K |
Interest Income | 416.69K | 180.42K | 51.70K | 447.00K | 984.93K | 0.00 | 0.00 | 485.49K | 11.16K | 28.06K | 14.61K | 695.85K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 894.53K | 566.15K | 909.00 | 11.16K | 683.21K | 686.02K | 0.00 | 594.16K | 710.54K | 597.91K | 0.00 |
Depreciation & Amortization | 0.00 | 10.12M | 3.49M | 9.96M | 9.25M | 7.40M | 7.38M | 5.81M | -2.17M | 271.13K | 253.50K | 256.48K | 250.18K | 602.73K | 586.69K | 0.00 |
EBITDA | -8.23M | -10.07M | -13.07M | -10.19M | -9.23M | -7.55M | -2.20M | 0.00 | -5.82M | -5.45M | 726.69K | 1.82M | -9.91M | -9.13M | -4.87M | -190.78K |
EBITDA Ratio | -283.90% | -343.51% | -671.40% | -635.84% | -548.88% | -582.88% | -1,580.02% | -897.71% | -1,842.27% | -39.11% | 4.33% | 11.65% | -71.47% | -60.63% | -27.04% | -90.30% |
Operating Income | -8.23M | -10.12M | -14.73M | -10.03M | -9.28M | -7.59M | -7.13M | -5.96M | -3.65M | -5.32M | 556.50K | 1.56M | -10.74M | -9.99M | -5.33M | -190.78K |
Operating Income Ratio | -283.90% | -345.21% | -612.67% | -625.85% | -552.18% | -586.09% | -939.70% | -1,004.45% | -1,154.93% | -42.52% | 3.25% | 10.00% | -69.78% | -62.87% | -31.82% | -90.30% |
Total Other Income/Expenses | 1.43M | 430.42K | 1.66M | 731.71K | 984.93K | 894.53K | 4.92M | 2.58M | 2.18M | 47.81K | -984.55K | -142.86K | -41.87K | -442.94K | -725.71K | 190.78K |
Income Before Tax | -6.80M | -9.74M | -13.07M | -9.29M | -8.30M | -6.70M | -2.20M | -3.37M | -1.47M | -5.98M | -428.05K | 1.42M | -10.82M | -10.45M | -6.07M | 0.00 |
Income Before Tax Ratio | -234.42% | -332.23% | -543.73% | -580.18% | -493.59% | -517.03% | -290.41% | -568.52% | -464.06% | -47.75% | -2.50% | 9.09% | -70.33% | -65.80% | -36.26% | 0.00% |
Income Tax Expense | 0.00 | -364.37K | -148.60K | 31.32K | 10.31K | -1.01M | -66.69K | 238.07K | -69.44M | 127.39K | 229.83K | 68.00K | 63.11K | 64.23K | 9.71K | 190.78K |
Net Income | -6.80M | -9.37M | -12.92M | -9.33M | -8.31M | -5.69M | -2.14M | -3.61M | 65.79M | -5.98M | -428.05K | 1.35M | -10.88M | -10.51M | -6.08M | -190.78K |
Net Income Ratio | -234.42% | -319.79% | -537.54% | -582.13% | -494.21% | -439.36% | -281.61% | -608.67% | 20,837.76% | -47.75% | -2.50% | 8.65% | -70.74% | -66.20% | -36.32% | -90.30% |
EPS | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.42 | -0.04 |
EPS Diluted | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.37 | -0.04 |
Weighted Avg Shares Out | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 33.74M | 24.42M | 22.13M | 14.39M | 5.00M |
Weighted Avg Shares Out (Dil) | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 34.23M | 24.42M | 22.13M | 16.32M | 5.00M |
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic to Attend Industry and Investor Events in May
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic Announces Change in Board and Management Leadership Roles
Dyadic to Attend Industry Events in April
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Source: https://incomestatements.info
Category: Stock Reports